ContextVision AB: Threshold exceeded for major shareholding notification due to repurchases of own shares
ContextVision AB: Threshold exceeded for major shareholding notification due to repurchases of own shares
Stockholm 21 October 2026 – ContextVision AB (publ) (“ContextVision” or the “Company”) hereby announces, in accordance with Chapter 4, Section 18 of the Swedish Financial Instruments Trading Act (1991:980), that on 19 October 2026 ContextVision acquired 15,086 own shares. ContextVision’s total holding of own shares thereafter amounted to 3,872,246 shares, which means that the Company’s holding of own shares amounted to 5.01 percent of the total number of shares and that the holding had therefore exceeded the threshold of 5 percent of the total number of shares in ContextVision.
The total number of shares in ContextVision amounts to 77,367,500 shares.
The repurchases form part of the share buy-back programme that ContextVision announced on 9 September 2026. Buy-backs may be made on one or several occasions from 10 September 2026 up to and including 29 January 2027. The maximum total amount for which shares may be repurchased may not exceed NOK 12,000,000, and the maximum number of shares that may be repurchased may not exceed 2,000,000 shares. DNB Carnegie is carrying out the buy-back programme under a mandate from ContextVision.
This is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Richard Hallström, CFO, on the time and date provided.
For further information, please contact:
Richard Hallström, CFO
Email: richard.hallstrom@contextvision.com
About ContextVision AB:
ContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world. Our expertise is to develop powerful software products, based on proprietary technology and artificial intelligence for image-based applications. Our cutting-edge technology helps clinicians accurately interpret medical images, a crucial foundation for better diagnosis and treatment. The company, established in 1983, is based in Sweden with local representation in the U.S., Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker CONTX.